Remynd NV is back on track with its novel septin-targeting Alzheimer’s disease program after addressing liver toxicity ...
At $446.3 million in gross proceeds, RNA-focused Adarx Pharmaceuticals Inc.’s IPO represents the fourth largest biopharma ...
The value of biopharma deals has generally trended upward, despite year-over-year and month-to-month volatility. BioWorld’s ...
New collaborations involving Henlius, Amberstone, Sanyou Bio and Novocodex highlight efforts to improve the safety, precision ...
Acadia Pharmaceuticals Inc.’s near miss disclosed Sept. 24 in phase II with 5HT2A receptor inverse agonist remlifanserin in ...
In a continuous effort to improve its cardiometabolic franchise, Novo Nordisk A/S entered a deal worth up to €1.165 billion ...
A complaint filed in 2023 by Nektar Therapeutics Inc. against former partner Eli Lilly and Co. regarding development of Treg stimulator rezpegaldesleukin (rezpeg) ended this week with the jury ...
Finnish newco Kasvu Therapeutics has raised €30 million (US$34.4 million) in a series A financing to take forward novel small ...
Eli Lilly and Co. has struck another major China partnership, signing a discovery-stage collaboration with Beijing-based ...
Merck & Co. Inc.’s positive top-line data from the pivotal phase IIb/III Brunello trial with remigromig in adults with ...
From the start, Heidi Overton’s confirmation hearing as U.S. FDA commissioner was shadowed by the broken promises Robert Kennedy made to the Senate Health, Education, Labor and Pensions Committee in ...
Even though the molecular and clinical genetics devices panel of the medical devices advisory committee for the U.S. FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results